Investing.com – The US Food and Drug Administration (FDA) has given pharmaceutical firm Abbott Laboratories (NYSE: ABT) an emergency authorization for its $ 5, credit card-sized COVID-19 antigen test, Market writes. Watch.
The compact and inexpensive test will be affordable and tasteful to many – it can be used anywhere: from the doctor's office or school nurse to the home environment, as it uses technology similar to pregnancy tests, and the answer can be received in 15 minutes …
The test has received emergency approval amid growing demand for massive access to COVID-19 diagnostic tools that provide immediate results – in minutes, not days, which will solve the problem of quickly localizing the infection.
Abbott said Wednesday that it plans to ship tens of millions of new tests to market in September, so the nation's bulk testing capacity will expand significantly. By October, she plans to send about 50 million tests.
So, if successful, the total number of tests in October will be roughly double the number of tests conducted in the US in July.
Several health officials and laboratory directors said inexpensive rapid tests that can be produced on a large scale are a major factor in enabling people to return to work and school.
Market Watch materials used in the preparation